Precigen anticipates funding through cash flow breakeven by end of 2026 as PAPZIMEOS launch scales
Precigen, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $4.12
-9.6% in 3d after detection
Post-detection moves
1h
—
1d
-3.9%
3d
-9.6%
7d
-7.8%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS